他汀联合降脂治疗.pptVIP

Combination niacin extended-release/lovastatin compared with statin alone (I) In a further review of the ADVOCATE data with a focus on relative effects on lipoprotein subclass distribution, at all doses tested: Niacin ER/lovastatin was more effective than either atorvastatin or simvastatin in increasing LDL peak particle diameter. Niacin ER/lovastatin was more effective than either atorvastatin or simvastatin in increasing proportion of HDL in cardioprotective 2b subclass (according to segmented gel electrophoresis). Reference: Bays HE, McGovern ME. Once-daily niacin extended-release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution compared to atorvastatin and simvastatin. Prev Cardiol 2003;6:179-188. * Combination niacin extended-release/lovastatin compared with statin alone (II) In a further review of the ADVOCATE data with a focus on relative effects on lipoprotein subclass distribution, at all doses tested: Niacin ER/lovastatin was more effective than either atorvastatin or simvastastin in reducing the proportion of LDL in atherogenic small, dense IIIa/IIIb subclasses. Niacin ER/lovastatin was more effective than either atorvastatin or simvastatin in reducing LDL pattern B prevalence. Reference: Bays HE, McGovern ME. Once-daily niacin extended-release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution compared to atorvastatin and simvastatin. Prev Cardiol 2003;6:179-188. * Niacin extended-release/lovastatin vs monotherapy with atorvastatin or simvastatin Isolated case reports have suggested an increased risk for liver and muscle toxicity with previous niacin preparations used in combination with statins. However, the ADVOCATE trial, using niacin extended-release [ER]/lovastatin in doses ranging from 500 mg/20 mg to 2000 mg/40 mg niacin ER/lovastatin, and atorvastatin or simvastatin monotherapy 10–40 mg, demonstrated that: 10 of